JAZZ - Jazz Pharma nears a six-month high as analysts cheer Q4 results

Jazz Pharmaceuticals (JAZZ +12.1%) has recorded the biggest intraday gain since 2017 on Wednesday to reach a six-month high on the strong Q4 earnings beat reported by the Neuroscience-focused biopharmaceutical company yesterday. Jazz (NASDAQ:JAZZ) reported more than $3B annual revenue for the first time in 2021, which was a “transformative year” for the company, according to its Chief Executive Bruce Cozadd. Total revenue for the quarter climbed ~35% YoY and ~31% YoY in Q4 and full-year 2021 to reach $896.7M and $3.1B, respectively. While Xyrem sales dropped ~34% YoY and ~274% YoY to $228.8M and $1.3B, the low sodium version of the drug, Xywav, brought $182.7M and $535.3M for Q4 and full-year 2021, respectively, up from $15.3M last year. During the quarter, Epidiolex/Epidyolex sales climbed ~35% YoY while Rylaze generated $65.0M net product sales. However, the company reported $35.3M and $329.7M net loss for Q4 and 2021 compared to net

For further details see:

Jazz Pharma nears a six-month high as analysts cheer Q4 results